The HHS Centers for Innovation in Advanced Development and Manufacturing has announced it will support work on a second-generation anthrax vaccine led by the Texas A&M University System in College Station.
Together, the CIADM and Texas A&M will launch advanced development and manufacturing activities for an investigational nasal spray vaccine under an 18-month, $10.49 million task order from the Office of the Assistant Secretary for Preparedness and Response's Biomedical Advanced Research and Development Authority.
"Anthrax remains a material threat to our national health security," said Acting BARDA Director Richard Hatchett, MD. "To help combat the health impacts of an anthrax attack, BARDA partnered with several biotechnology firms in accelerating development of promising next-generation treatments against anthrax infection. Engaging one of our Centers for Innovation in Advanced Development and Manufacturing represents a unique approach to this development."
More articles on vaccines:
Malaria vaccine test produces best results so far
Physician access to vaccine records linked to higher immunization rates
Zika vaccine testing could begin in September